Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7363127 | 0.94 | MAOA (0.51) | MAOAMAOBHRH3 | |
| SCHEMBL7368135 | 0.92 | MAOA (0.50) | MAOAMAOBHRH3 | |
| SCHEMBL1097715 | 0.86 | — | — | |
| SCHEMBL21084371 | 0.84 | MAOA (0.48) | MAOAMAOBHRH3 | |
| SCHEMBL7235805 | 0.78 | MAOA (0.53) | MAOAMAOBHRH3 | |
| SCHEMBL7066688 | 0.78 | MAOA (0.53) | MAOAMAOB | |
| SCHEMBL1099182 | 0.78 | MAOA (0.53) | MAOAMAOBHRH3 | |
| SCHEMBL1099184 | 0.78 | MAOA (0.53) | MAOAMAOBHRH3 | |
| SCHEMBL7066686 | 0.78 | MAOA (0.53) | MAOAMAOBHRH3 | |
| SCHEMBL8169120 | 0.78 | MAOA (0.53) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101072758-B | Quinazoline derivatives | ASTRAZENECA AB | 2013-07-31 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20120165351-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| US-8153643-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| EP-1802591-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-01-11 | — | — | EP | disclosed |
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | disclosed |
| US-20090233950-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090233924-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| CN-101437810-A | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-05-20 | — | — | CN | disclosed |
| WO-2004069827-A1 | QUINOLINE DERIVATIVES AND USE THEREOF AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004056812-A1 | 4- (PYRIDIN-4-YLAMINO) -QUINAZOLINE DERIVATIVES AS ANTI-TUMOR AGENTS | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056801-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004041829-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | disclosed |
| WO-2003047585-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING BENZOFURANYL SUBSTITUTED 3-CYANOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SOLID TUMOURS | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003047583-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING BENZOFURANYL SUBSTITUTED 3-CYANOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SOLID TUMOURS | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003048159-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |
| US-5137889-A | Hypotensive agents; coronary vasodilators; calcium antagonists; antiinflammatory agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-11 | — | — | US | disclosed |
| US-5034395-A | Hypotensive agents, carboxylated dihydropyridines | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-23 | — | — | US | disclosed |
| EP-0145434-A2 | Novel dihydropyridine derivatives and process for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233924-A1 | Quinazoline derivatives | AQP1, PGF, F12 | MAOA 3014/4885MAOB 2535/4885HRH3 209/4885 |
| US-20090233950-A1 | QUINAZOLINE DERIVATIVES | NQO2, CCNI, F12 | MAOA 2990/4885MAOB 2804/4885HRH3 169/4885 |
| US-20120165351-A1 | QUINAZOLINE DERIVATIVES | AQP1, F12, AQP3 | MAOA 3199/4885MAOB 2981/4885HRH3 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.